• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Michael Fitzhugh

Articles by Michael Fitzhugh

Allergan to pay $2.9B for Lifecell, driven in part by breast cancer

Dec. 28, 2016
By Michael Fitzhugh
Allergan plc said it will buy Lifecell Corp., a company that makes regenerative medicine products for tissue reinforcement, from privately held Acelity LP for $2.9 billion in cash, a purchase partly driven by growing demand for reconstructive breast surgeries among women with breast cancer. About one in eight U.S. women will develop invasive breast cancer over the course of their lifetime, and, globally, breast cancer now represents one in four of all cancers in women, the company said, citing statistics from the nonprofit Breastcancer.org. The acquisition will add a portfolio of dermal matrix products used...
Read More

Allergan to pay $2.9B for Lifecell, driven in part by breast cancer

Dec. 21, 2016
By Michael Fitzhugh
Allergan plc said it will buy Lifecell Corp., a company that makes regenerative medicine products for tissue reinforcement, from privately held Acelity LP for $2.9 billion in cash, a purchase partly driven by growing demand for reconstructive breast surgeries among women with breast cancer.
Read More

Allergan to pay $2.9B for Lifecell, partly driven by breast cancers

Dec. 21, 2016
By Michael Fitzhugh
Allergan plc said it will buy Lifecell Corp., a company that makes regenerative medicine products for tissue reinforcement, from privately held Acelity LP for $2.9 billion in cash, a purchase partly driven by growing demand for reconstructive breast surgeries among women with breast cancer.
Read More

Tonix Pharmaceuticals lands breakthrough status for PTSD drug

Dec. 20, 2016
By Michael Fitzhugh
Just months after a phase III trial miss for TNX-102 SL in fibromyalgia elevated post-traumatic stress disorder (PTSD) to the lead indication for the Tonix Pharmaceuticals Holding Corp. drug, it has secured FDA breakthrough status in the condition, which is often tied to military combat trauma.
Read More

Phase II trial of Vtv's GLP-1 receptor agonist shows reduced HbA1c

Dec. 16, 2016
By Michael Fitzhugh
Vtv Therapeutics Inc. reported that its oral GLP-1 receptor agonist, TTP273, helped type 2 diabetics on stable doses of metformin achieve mean placebo-subtracted HbA1c differences of up to -0.86 percent during a phase II study, giving it confidence to continue advancing the program, one of two diabetes-focused efforts at the company.
Read More

Third Rock founds kidney-focused Goldfinch with $55M series A

Dec. 15, 2016
By Michael Fitzhugh
Third Rock Ventures LLC has invested $55 million in a series A financing of Goldfinch Bio, a new Cambridge, Mass.-based company founded to discover and develop precision kidney disease therapies for conditions including focal segmental glomerulosclerosis (FSGS) and polycystic kidney disease. Using a patient registry to collect and integrate genomic and phenotypic data, it will focus on helping molecularly defined patient groups.
Read More

Bayer, Versant launch regenerative medicine venture Bluerock with $225M series A

Dec. 13, 2016
By Michael Fitzhugh
Partners Bayer AG and Versant Ventures have committed $225 million in series A financing to launch Bluerock Therapeutics, a regenerative medicine company focused on developing induced pluripotent stem cell therapies for diseases with significant cell loss and diminished self-repair potential.
Read More

U.S. federal agencies pledge up to $1.1B for Emergent Biosolutions' anthrax vaccine

Dec. 12, 2016
By Michael Fitzhugh
Emergent Biosolutions Inc. has lined up federal support for follow-on purchases of up to $1.1 billion of its anthrax vaccines that will keep the strategic national stockpile fresh as the government prepares for an anticipated 2019 transition.
Read More

TCR2 secures $44.5M series A to back cancer immunotherapy platform

Dec. 9, 2016
By Michael Fitzhugh
TCR2 Therapeutics Inc., a Cambridge, Mass.-based immunotherapy developer targeting solid tumors with an approach to T-cell therapies that its execs say will improve safety and durability, has landed a $44.5 million series A financing expected to carry its anticancer aspirations into the clinic by the end of 2018.
Read More

Heat Biologics shares melt as cancer vaccine disappoints

Dec. 2, 2016
By Michael Fitzhugh
Top-line data from a trial of HS-410 (vesigenurtacel-L), Heat Biologics Inc.'s experimental non-muscle invasive bladder cancer (NMIBC) vaccine, fell short of hitting its primary endpoint in a phase II study, robbing the Durham, N.C.-based company of a desired chance to seek an accelerate approval in phase III, but not of its hope for success, CEO and founder Jeff Wolf told BioWorld Today.
Read More
Previous 1 2 … 119 120 121 122 123 124 125 126 127 … 179 180 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 23, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 20, 2025
  • Drug capsule and dollar sign

    Little bite from voluntary most-favored nation Rx pricing order

    BioWorld
    After a week of hype, the most-favored nation (MFN) drug pricing executive order (EO) U.S. President Donald Trump signed May 12 has a lot of bark but little bite,...
  • Illustration of liver with DNA double helixes

    ASGCT 2025: Gene and cell therapies transform metabolic diseases

    BioWorld Science
    Metabolic disorders such as argininosuccinic and glutaric aciduria, methylmalonic acidemia, homocystinuria or primary hyperoxaluria require specific diets to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe